ARWR Stock Overview
Develops medicines for the treatment of intractable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.54 |
| 52 Week High | US$39.83 |
| 52 Week Low | US$17.05 |
| Beta | 0.93 |
| 11 Month Change | -7.76% |
| 3 Month Change | -24.94% |
| 1 Year Change | -36.33% |
| 33 Year Change | -74.26% |
| 5 Year Change | -74.61% |
| Change since IPO | -64.35% |
Recent News & Updates
Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Shareholder Returns
| ARWR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | 2.5% | 2.2% |
| 1Y | -36.3% | 16.1% | 31.6% |
Return vs Industry: ARWR underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: ARWR underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ARWR volatility | |
|---|---|
| ARWR Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARWR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARWR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| ARWR fundamental statistics | |
|---|---|
| Market cap | US$2.30b |
| Earnings (TTM) | -US$538.64m |
| Revenue (TTM) | US$19.65m |
117.3x
P/S Ratio-4.3x
P/E RatioIs ARWR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARWR income statement (TTM) | |
|---|---|
| Revenue | US$19.65m |
| Cost of Revenue | US$0 |
| Gross Profit | US$19.65m |
| Other Expenses | US$558.28m |
| Earnings | -US$538.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -4.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,741.43% |
| Debt/Equity Ratio | 99.1% |
How did ARWR perform over the long term?
See historical performance and comparison